Acquisition of Zavante (Details) - Zavante Therapeutics $ in Millions	Jul. 24, 2018 USD ($) shares
Acquisition of Zavante
Percentage of entity shares held by subsidiary	19.90%
Milestone payment receivable prior acquisition	$ 3.0
Threshold milestone payment that may be settled in ordinary shares	26.0
In-process research and development expense	32.0
Transaction costs	4.8
Net liabilities assumed	0.2
Maximum
Acquisition of Zavante
Contingent consideration	$ 97.5
Upfront Shares
Acquisition of Zavante
Business acquisition, shares issued or issuable | shares	733,690
Expense from the fair value of shares issued in the acquisition	$ 26.9
Holdback Shares
Acquisition of Zavante
Business acquisition, shares issued or issuable | shares	81
Approval Milestone Payment
Acquisition of Zavante
Contingent consideration	$ 25.0
Net Sales Milestone Payments
Acquisition of Zavante
Contingent consideration	$ 72.5